HRV-39

PreclinicalBiologic

UUniversity of Calgary

HRV-39 is one of 25 biologic programs targeting Asthma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AsthmaActive, not recruiting

AsthmaPreclinical

Active, not recruiting

Competition

Competitive Landscape

161 competitors in Asthma

#DrugCompanyPhaseTrials

Celexa

AbbVie

Preclinical

1 2

Arcoxia

Novartis

Preclinical

—3

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 4

DUPIXENT

Regeneron

Preclinical

1 5

Paracetamol

GSK

Preclinical

1 6

Blood Withdrawn

Emergent BioSolutions

Preclinical

1 7

Aclidinium Bromide

Atrovent

2 9

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 10

Lexapro

SShirley Ryan AbilityLab

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Asthma1 trial

Airway Remodeling and Rhinovirus in Asthmatics

Recruiting·UUniversity of Calgary··NCT05775952·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HRV-39. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HRV-39 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HRV-39. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Calgary company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Calgary

HRV-39

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Asthma1 trial

References

Drug Info

Quick Facts

Related News